K
The startup develops Antisense Oligonucleotide (AON) therapy to selectively silence cancer-causing genes by targeting the translation process of specific DNA sequences into disease-causing proteins. This approach minimizes toxicity by allowing the drug to focus on cancer cells while sparing normal cells, thereby reducing side effects associated with traditional cancer treatments.
Vancouver, Canada
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops Antisense Oligonucleotide (AON) therapy to selectively silence cancer-causing genes by targeting the translation process of specific DNA sequences into disease-causing proteins. This approach minimizes toxicity by allowing the drug to focus on cancer cells while sparing normal cells, thereby reducing side effects associated with traditional cancer treatments.